GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intelgenx Technologies Corp (TSX:IGX) » Definitions » EV-to-EBIT

Intelgenx Technologies (TSX:IGX) EV-to-EBIT : -5.12 (As of Oct. 31, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Intelgenx Technologies EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Intelgenx Technologies's Enterprise Value is C$61.47 Mil. Intelgenx Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was C$-12.02 Mil. Therefore, Intelgenx Technologies's EV-to-EBIT for today is -5.12.

The historical rank and industry rank for Intelgenx Technologies's EV-to-EBIT or its related term are showing as below:

TSX:IGX' s EV-to-EBIT Range Over the Past 10 Years
Min: -117.15   Med: -5.47   Max: 418.37
Current: -5.02

During the past 13 years, the highest EV-to-EBIT of Intelgenx Technologies was 418.37. The lowest was -117.15. And the median was -5.47.

TSX:IGX's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 10.01 vs TSX:IGX: -5.02

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Intelgenx Technologies's Enterprise Value for the quarter that ended in Mar. 2024 was C$62.27 Mil. Intelgenx Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was C$-12.02 Mil. Intelgenx Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -19.30%.


Intelgenx Technologies EV-to-EBIT Historical Data

The historical data trend for Intelgenx Technologies's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelgenx Technologies EV-to-EBIT Chart

Intelgenx Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.40 -5.51 -7.23 -4.51 -4.50

Intelgenx Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.30 -4.59 -3.80 -4.50 -5.20

Competitive Comparison of Intelgenx Technologies's EV-to-EBIT

For the Biotechnology subindustry, Intelgenx Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intelgenx Technologies's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intelgenx Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Intelgenx Technologies's EV-to-EBIT falls into.



Intelgenx Technologies EV-to-EBIT Calculation

Intelgenx Technologies's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=61.473/-12.016
=-5.12

Intelgenx Technologies's current Enterprise Value is C$61.47 Mil.
Intelgenx Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-12.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intelgenx Technologies  (TSX:IGX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Intelgenx Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-12.016/62.27463
=-19.30 %

Intelgenx Technologies's Enterprise Value for the quarter that ended in Mar. 2024 was C$62.27 Mil.
Intelgenx Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-12.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intelgenx Technologies EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Intelgenx Technologies's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Intelgenx Technologies Business Description

Traded in Other Exchanges
N/A
Address
6420 Abrams, Ville Saint Laurent, QC, CAN, H4S 1Y2
Intelgenx Technologies Corp is an oral drug delivery company. The company is focused on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilmTM technology platform. The company focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers a comprehensive portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, tech transfer, and manufacturing scale-up, and commercial manufacturing. Its geographical segments are Europe, Canada, and the United States. The company generates the majority of its revenue from Europe.
Executives
Dana Matzen Senior Officer
André Godin Senior Officer
Tommy Kenny Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
James Bernard Boudreau Director
Ingrid Zerbe 10% Security Holder

Intelgenx Technologies Headlines

No Headlines